0.9599

2.07% 0.0195

After Hours: .96 0.000100 +0.01%

Tempest Therapeutics Inc (TPST)

Overview News Price History Option Chain Financials Why TPST Down? Discussions Forecast Stock Split

Tempest Therapeutics Inc stock is traded at $0.9599, with a volume of 857.49K. It is up +2.07% in the last 24 hours and down -11.94% over the past month. Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.

Previous Close:

$0.9404

Open:

$0.941

24h Volume:

857.49K

Relative Volume:

0.29

Market Cap:

$41.78M

Revenue:

Net Income/Loss:

$-31.11M

P/E Ratio:

-0.4033

EPS:

-2.38

Net Cash Flow:

$-28.18M

1W Performance:

+6.85%

1M Performance:

-11.94%

6M Performance:

-70.42%

1Y Performance:

-74.54%

1-Day Range:

$0.925

$0.9787

1-Week Range:

$0.8656

$0.9849

52-Week Range:

$0.80

$6.00

Tempest Therapeutics Inc Stock (TPST) Company Profile

Name

Tempest Therapeutics Inc

Sector

Healthcare (1200)

Industry

Biotechnology (682)

Phone

415-798-8589

Address

2000 SIERRA POINT PARKWAY, BRISBANE

Employee

Twitter

Next Earnings Date

2024-11-06

Latest SEC Filings

TPST's Discussions on Twitter

Compare TPST with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TPST Tempest Therapeutics Inc	0.9599	41.78M	0	-31.11M	-28.18M	-2.38
VRTX Vertex Pharmaceuticals Inc	464.56	119.70B	10.63B	-479.80M	-1.35B	13.33
REGN Regeneron Pharmaceuticals Inc	754.87	82.75B	13.85B	4.65B	3.32B	35.06
ARGX Argen X Se Adr	614.59	36.73B	1.86B	-40.29M	-1.28B	-4.16
ALNY Alnylam Pharmaceuticals Inc	253.74	32.53B	2.09B	-332.26M	16.06M	-4.14
BNTX Biontech Se Adr	120.72	28.50B	3.30B	-501.07M	1.03B	11.54

Tempest Therapeutics Inc Stock (TPST) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-14-24	Initiated	Scotiabank	Sector Outperform
Feb-08-24	Initiated	Jefferies	Buy

Tempest Therapeutics Inc Stock (TPST) Latest News

Nov 27, 2024

Favourable Signals For Tempest Therapeutics: Numerous Insiders Acquired Stock - Yahoo Finance

Nov 27, 2024

Nov 25, 2024

Tempest to Participate in the Piper Sandler 36th Annual Healthcare Conference - GlobeNewswire

Nov 25, 2024

Nov 18, 2024

TPST Stock Plummets to 52-Week Low at $0.85 Amid Market Struggles - Investing.com

Nov 15, 2024

HC Wainwright Reiterates “Buy” Rating for Tempest Therapeutics (NASDAQ:TPST) - Defense World

Nov 15, 2024

Nov 13, 2024

Tempest Therapeutics Reports Q3 2024 Financial Results - TipRanks

Nov 13, 2024

Tempest Therapeutics price target lowered to $5 from $8 at Piper Sandler - TipRanks

Nov 13, 2024

TPSTTempest Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Nov 13, 2024

Nov 12, 2024

Tempest Therapeutics advances liver cancer drug to Phase 3 trial By Investing.com - Investing.com Canada

Nov 12, 2024

Tempest Therapeutics reports Q3 EPS (41c), consensus (36c) - TipRanks

Nov 12, 2024

Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire

Nov 12, 2024

Tempest Therapeutics advances liver cancer drug to Phase 3 trial - Investing.com India

Nov 12, 2024

Tempest Receives FDA Study May Proceed for Pivotal Phase 3 - GlobeNewswire

Nov 12, 2024

Tempest Gets FDA Green Light for Pivotal Phase 3 Liver Cancer Drug Trial | TPST Stock | TPST Stock News - StockTitan

Nov 12, 2024

Oct 30, 2024

TPST stock touches 52-week low at $0.91 amid market challenges - Investing.com UK

Oct 30, 2024

Oct 16, 2024

Take off with Tempest Therapeutics Inc (TPST): Get ready for trading - SETE News

Oct 16, 2024

Oct 15, 2024

Market Momentum: Tempest Therapeutics Inc (TPST) Registers a 4.39 Increase, Closing at 1.07 - The Dwinnex

Oct 15, 2024

Oct 14, 2024

TPST stock touches 52-week low at $0.92 amid market challenges By Investing.com - Investing.com South Africa

Oct 14, 2024